| [1] |
Estrella-Alonso A, Aramburu JA, González-Ruiz MY, et al. Toxic epidermal necrolysis: a paradigm of critical illness[J]. Rev Bras Ter Intensiva, 2017, 29(4): 499-508. DOI: 10.5935/0103-507X.20170075.
doi: 10.5935/0103-507X.20170075
|
| [2] |
Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016[J]. J Plast Reconstr Aesthet Surg, 2016, 69(6): e119-e153. DOI: 10.1016/j.bjps.2016.01.034.
doi: 10.1016/j.bjps.2016.01.034
pmid: 27287213
|
| [3] |
Wang YH, Chen CB, Tassaneeyakul W, et al. The medication risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label[J]. Clin Pharmacol Ther, 2019, 105(1): 112-120. DOI: 10.1002/cpt.1071.
doi: 10.1002/cpt.1071
|
| [4] |
Trent J, Halem M, French LE, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review[J]. Semin Cutan Med Surg, 2006, 25(2): 91-93. DOI: 10.1016/j.sder.2006.04.004.
doi: 10.1016/j.sder.2006.04.004
|
| [5] |
胡雪, 曹雪, 宋燕青, 等. 头孢菌素类药物致史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的文献分析[J]. 中国医院药学杂志, 2021, 41(8): 840-845. DOI: 10.13286/j.1001-5213.2021.08.14.
doi: 10.13286/j.1001-5213.2021.08.14
|
| [6] |
徐利君, 李星霞. 左氧氟沙星疑致中毒性表皮坏死松解型药疹1例[J]. 中国药物应用与监测, 2015, 12(4): 258-260.
|
| [7] |
陈魁霞, 潘丹, 李立, 等. 左氧氟沙星注射液致中毒性表皮坏死松解症[J]. 药物不良反应杂志, 2020, 22(9): 537-538. DOI: 10.3760/cma.j.cn114015-20190904-00734.
doi: 10.3760/cma.j.cn114015-20190904-00734
|
| [8] |
Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab[J]. J Oncol Pharm Pract, 2020, 26(5): 1259-1265. DOI: 10.1177/1078155219890659.
doi: 10.1177/1078155219890659
|
| [9] |
何琳, 陈适, 夏陈英, 等. 1例卡瑞利珠单抗致中毒性表皮坏死松解症并文献复习[J]. 中南药学, 2021, 19(8): 1751-1754. DOI: 10.7539/j.issn.1672-2981.2021.08.049.
doi: 10.7539/j.issn.1672-2981.2021.08.049
|
| [10] |
邓爱清, 殷晓芹, 朱秋燕, 等. 替雷利珠单抗相关中毒性表皮坏死松解症1例[J]. 中国医院药学杂志, 2021, 41(19): 2039-2040. DOI: 10.13286/j.1001-5213.2021.19.22.
doi: 10.13286/j.1001-5213.2021.19.22
|
| [11] |
李欣, 刘玉, 韩建文. 中毒性表皮坏死松解症17例临床分析[J]. 临床皮肤科杂志, 2020, 49(8): 465-467. DOI: 10.16761/j.cnki.1000-4963.2020.08.006.
doi: 10.16761/j.cnki.1000-4963.2020.08.006
|
| [12] |
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68. DOI: 10.1038/clpt.2009.252.
doi: 10.1038/clpt.2009.252
pmid: 20375998
|
| [13] |
Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000, 115(2): 149-153. DOI: 10.1046/j.1523-1747.2000.00061.x.
doi: 10.1046/j.1523-1747.2000.00061.x
pmid: 10951229
|
| [14] |
Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges[J]. J Hematol Oncol, 2018, 11(1): 39. DOI: 10.1186/s13045-018-0582-8.
doi: 10.1186/s13045-018-0582-8
|
| [15] |
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3): 345-361. DOI: 10.1007/s40257-017-0336-3.
doi: 10.1007/s40257-017-0336-3
|
| [16] |
Choonhakarn C, Limpawattana P, Chaowattanapanit S. Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis: a retrospective study[J]. J Dermatol, 2016, 43(2): 156-161. DOI: 10.1111/1346-8138.13040.
doi: 10.1111/1346-8138.13040
|
| [17] |
Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. DOI: 10.6004/jnccn.2020.0012.
doi: 10.6004/jnccn.2020.0012
|
